Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Turning Point Therapeutics stock | $46.83

Learn how to easily invest in Turning Point Therapeutics stock.

Turning Point Therapeutics Inc is a biotechnology business based in the US. Turning Point Therapeutics shares (TPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Turning Point Therapeutics employs 201 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Turning Point Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TPTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Turning Point Therapeutics stock price (NASDAQ: TPTX)

Use our graph to track the performance of TPTX stocks over time.

Turning Point Therapeutics shares at a glance

Information last updated 2021-10-10.
Latest market close$46.83
52-week range$46.26 - $141.30
50-day moving average $73.12
200-day moving average $72.80
Wall St. target price$138.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.36

Buy Turning Point Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Turning Point Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Turning Point Therapeutics price performance over time

Historical closes compared with the close of $46.83 from 2021-10-15

1 week (2021-10-08) -1.95%
1 month (2021-09-16) -40.42%
3 months (2021-07-16) -30.47%
6 months (2021-04-16) -35.88%
1 year (2020-10-16) -59.27%
2 years (2019-10-16) 26.60%
3 years (2018-10-12) N/A
5 years (2016-10-12) N/A

Turning Point Therapeutics financials

Revenue TTM $55.4 million
Gross profit TTM $25 million
Return on assets TTM -10.5%
Return on equity TTM -17.64%
Profit margin -283.3%
Book value $21.61
Market capitalisation $2.4 billion

TTM: trailing 12 months

Shorting Turning Point Therapeutics shares

There are currently 2.4 million Turning Point Therapeutics shares held short by investors – that's known as Turning Point Therapeutics's "short interest". This figure is 6.4% down from 2.5 million last month.

There are a few different ways that this level of interest in shorting Turning Point Therapeutics shares can be evaluated.

Turning Point Therapeutics's "short interest ratio" (SIR)

Turning Point Therapeutics's "short interest ratio" (SIR) is the quantity of Turning Point Therapeutics shares currently shorted divided by the average quantity of Turning Point Therapeutics shares traded daily (recently around 271588.44393593). Turning Point Therapeutics's SIR currently stands at 8.74. In other words for every 100,000 Turning Point Therapeutics shares traded daily on the market, roughly 8740 shares are currently held short.

However Turning Point Therapeutics's short interest can also be evaluated against the total number of Turning Point Therapeutics shares, or, against the total number of tradable Turning Point Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Turning Point Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Turning Point Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0538% of the tradable shares (for every 100,000 tradable Turning Point Therapeutics shares, roughly 54 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Turning Point Therapeutics.

Find out more about how you can short Turning Point Therapeutics stock.

Turning Point Therapeutics share dividends

We're not expecting Turning Point Therapeutics to pay a dividend over the next 12 months.

Turning Point Therapeutics share price volatility

Over the last 12 months, Turning Point Therapeutics's shares have ranged in value from as little as $46.26 up to $141.3. A popular way to gauge a stock's volatility is its "beta".

TPTX.US volatility(beta: 1.08)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Turning Point Therapeutics's is 1.0761. This would suggest that Turning Point Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Turning Point Therapeutics overview

Turning Point Therapeutics, Inc. , a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0022, a MET/CSF1R/SRC inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in Phase 1/2 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, a preclinical ALK inhibitor for advanced non-small-cell lung cancer. The company was founded in 2013 and is headquartered in San Diego, California. .

Frequently asked questions

What percentage of Turning Point Therapeutics is owned by insiders or institutions?
Currently 3.644% of Turning Point Therapeutics shares are held by insiders and 100.135% by institutions.
How many people work for Turning Point Therapeutics?
Latest data suggests 201 work at Turning Point Therapeutics.
When does the fiscal year end for Turning Point Therapeutics?
Turning Point Therapeutics's fiscal year ends in December.
Where is Turning Point Therapeutics based?
Turning Point Therapeutics's address is: 10628 Science Center Drive, San Diego, CA, United States, 92121
What is Turning Point Therapeutics's ISIN number?
Turning Point Therapeutics's international securities identification number is: US90041T1088
What is Turning Point Therapeutics's CUSIP number?
Turning Point Therapeutics's Committee on Uniform Securities Identification Procedures number is: 90041T108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site